Modeling analysis finds psilocybin-assisted therapy cost-effective for treatment-resistant depression, suggesting potential benefits for patient care.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ziadi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: